FDA Approves Alhemo for Patients with Hemophilia
Routine prophylaxis to prevent or reduce bleedingFor Patients with Hemophilia A or B with Inhibitors
The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:
- Hemophilia A with factor VIII inhibitors, or
- Hemophilia B with factor IX inhibitors.
What It Is
- Alhemo is a subcutaneous (under the skin) injection, taken daily.
- It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.
Effectiveness
- In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
- Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.
Safety Info
- Most common side effects: Injection site reactions and hives.
- May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
- Not recommended for patients with serious allergies to the drug or its ingredients.
Special FDA Designations
- Priority Review
- Orphan Drug status (for rare conditions)
Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
Ethicon Issues Safety Alert for Surgical Stapler Cartridge
Endopath Echelon Vascular White Reload for Advanced Placement TipSource: FDAUrgent Class I Medical Device Recall Ethicon Endo-Surgery, LLC has issued an urgent correction for its Endopath Echelon Vascular White Reload for Advanced Placement Tip (35 mm, 4-row). This...
Urgent Recall of Codman Disposable Perforators
Urgent Class I Medical Device Recall Integra LifeSciences has issued an urgent recall of specific Codman Disposable Perforators and Craniotomy Kits due to a serious manufacturing defect that may lead to device disassembly during neurosurgical procedures. The FDA has...
FDA Cracks Down on Illegally Marketed 7-OH Products
Unapproved drugs sold online and in retail locations Yesterday the U.S. Food and Drug Administration (FDA) issued seven warning letters to companies marketing products that contain 7-hydroxymitragynine (7-OH) — a powerful and potentially dangerous opioid-like...